Literature DB >> 8341216

Chemotherapy in the management of infantile fibrosarcoma.

J A Kynaston1, A J Malcolm, A W Craft, S M Davies, P H Jones, D J King, C D Mitchell, A Oakhill, C A Stiller.   

Abstract

Infantile fibrosarcoma (IF) has traditionally been treated with surgery, which may have considerable morbidity. Chemotherapy has been suggested in order to reduce the need for extensive surgery. Nine children with histologically confirmed IF who received chemotherapy are described. Six children were treated with chemotherapy initially, two following conservative surgery, and one following recurrence after surgery. All received vincristine (V) and actinomycin D (A), and six received additional drugs including ifosfamide (I), cyclophosphamide (C), adriamycin (Ad), etoposide (E), and cisplatinum (CDDP). Objective responses were achieved in eight: three responded completely (CR), two responded partially (PR), which allowed conservative surgery, one had stable disease, one had an initial PR, but subsequently had tumour recurrence 1 month after cessation of treatment, necessitating further surgery and chemotherapy, and one had an initial PR but died following local and regional metastases. One child had no response to chemotherapy but is alive with stable residual disease. Thus, five of nine children achieved a CR--three with chemotherapy alone. With the inclusion of chemotherapy as part of their treatment, five children, for whom curative surgery may have resulted in amputation, remain alive with limbs intact. Chemotherapy including V and A should be given to infants with fibrosarcoma in whom curative surgery would be mutilating.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341216     DOI: 10.1002/mpo.2950210706

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  6 in total

1.  Orthopaedic case of the month: Rapidly progressive shoulder soft tissue mass in an 8-week-old girl.

Authors:  Nicole Marie Behnke; Moneil Patel; Tom Davidson; Alexandre Arkader
Journal:  Clin Orthop Relat Res       Date:  2010-12-03       Impact factor: 4.176

2.  Clinical management of infantile fibrosarcoma: a retrospective single-institution review.

Authors:  Lalit Parida; Israel Fernandez-Pineda; John K Uffman; Andrew M Davidoff; Matthew J Krasin; Alberto Pappo; Bhaskar N Rao
Journal:  Pediatr Surg Int       Date:  2013-05-26       Impact factor: 1.827

3.  Margin status and multimodal therapy in infantile fibrosarcoma.

Authors:  Jason P Sulkowski; Mehul V Raval; Marybeth Browne
Journal:  Pediatr Surg Int       Date:  2013-06-14       Impact factor: 1.827

4.  Secondary fibrosarcoma of the brain stem treated with cyclophosphamide and Imatinib.

Authors:  Daniela Alexandru; Denise K Van Horn; Daniela Annenelie Bota
Journal:  J Neurooncol       Date:  2009-12-31       Impact factor: 4.130

5.  Infantile fibrosarcoma in a child: a case report.

Authors:  A Hashemi; S Tefagh; A Seifadini; M Moghimi
Journal:  Iran J Ped Hematol Oncol       Date:  2013-07-22

6.  Infantile fibrosarcoma-like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib.

Authors:  Ajay Gupta; Jennifer A Belsky; Kathleen M Schieffer; Kristen Leraas; Elizabeth Varga; Sean D McGrath; Selene C Koo; Vincent Magrini; Richard K Wilson; Peter White; Elaine R Mardis; Kris R Jatana; Catherine E Cottrell; Bhuvana A Setty
Journal:  Cold Spring Harb Mol Case Stud       Date:  2020-10-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.